Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 2
2012 4
2014 1
2017 1
2018 2
2019 1
2020 2
2021 4
2022 1
2023 2
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K, Haj Mohammad SF, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. Taskén K, et al. Acta Oncol. 2024 May 23;63:385-391. doi: 10.2340/1651-226X.2024.34791. Acta Oncol. 2024. PMID: 38779910 Free PMC article.
[BREAST registry].
Grell P, Hejduk K, Vyzula R. Grell P, et al. Klin Onkol. 2012;25(3):216-8. Klin Onkol. 2012. PMID: 22754973 Czech. No abstract available.
Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers.
Champiat S, Garralda E, Galvao V, Cassier PA, Gomez-Roca C, Korakis I, Grell P, Naing A, LoRusso P, Mikyskova R, Podzimkova N, Reinis M, Ouali K, Schoenenberger A, Kiemle-Kallee J, Tillmanns S, Sachse R, Moebius U, Spisek R, Bechard D, Jelinkova LP, Adkins I, Marabelle A. Champiat S, et al. Among authors: grell p. Cell Rep Med. 2025 Feb 18;6(2):101967. doi: 10.1016/j.xcrm.2025.101967. Epub 2025 Feb 10. Cell Rep Med. 2025. PMID: 39933529 Free PMC article. Clinical Trial.
A Phase I Dose-Escalation Study of the HIF-2 Alpha Inhibitor DFF332 in Patients with Advanced Clear-Cell Renal Cell Carcinoma.
Pal SK, Bernard-Tessier A, Grell P, Gao X, Kotecha RR, Picus J, de Braud F, Takahashi S, Wong A, Suárez C, Otero JA, Kundamal N, Yang X, Sharaby S, Roy M, Barzaghi-Rinaudo P, Tannir NM. Pal SK, et al. Among authors: grell p. Clin Cancer Res. 2025 May 15;31(10):1847-1855. doi: 10.1158/1078-0432.CCR-24-2618. Clin Cancer Res. 2025. PMID: 40043000 Free PMC article. Clinical Trial.
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial.
Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, Schenker M, Bratland Å, Walker JWT, Grell P, Even C, Chung CH, Redman R, Coutte A, Salas S, Grant C, de Azevedo S, Soulières D, Hansen AR, Wei L, Khan TA, Miller-Moslin K, Roberts M, Haddad R. Harrington KJ, et al. Among authors: grell p. JAMA Oncol. 2023 Jun 1;9(6):779-789. doi: 10.1001/jamaoncol.2023.0147. JAMA Oncol. 2023. PMID: 37022706 Free PMC article.
N-glycan profiling of tissue samples to aid breast cancer subtyping.
Benesova I, Nenutil R, Urminsky A, Lattova E, Uhrik L, Grell P, Kokas FZ, Halamkova J, Zdrahal Z, Vojtesek B, Novotny MV, Hernychova L. Benesova I, et al. Among authors: grell p. Sci Rep. 2024 Jan 3;14(1):320. doi: 10.1038/s41598-023-51021-3. Sci Rep. 2024. PMID: 38172220 Free PMC article.
27 results